First Berlin Research Starts Lisata Therapeutics, Inc (LSTA) at Buy, 'We see 2025 as an exciting year for Lisata as we also expect results on the other ongoing trials of certepetide'
Tweet Send to a Friend
First Berlin Research analyst Christian Orquera initiates coverage on Lisata Therapeutics, Inc (NASDAQ: LSTA) with a Buy rating and a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
